Showing results (101-110 of 212) with videos related to

Sort By:
Pageof 22
Psychoneuroendocrinology|October 23, 2012
Schizophrenia: metabolic aspects of aetiology, diagnosis and future treatment strategiesLaura W Harris, Paul C Guest, Matthew T Wayland, et al.
Journal of Proteome Research|September 10, 2008
High throughput lipidomic profiling of schizophrenia and bipolar disorder brain tissue reveals alterations of free fatty acids, phosphatidylcholines, and ceramidesEmanuel Schwarz, Sudhakaran Prabakaran, Phil Whitfield, et al.
Molecular & Cellular Proteomics : MCP|March 20, 2008
Increased alpha-defensins as a blood marker for schizophrenia susceptibilityRachel M Craddock, Jeffrey T Huang, Edmund Jackson, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|November 28, 2012
Electroconvulsive therapy exerts mainly acute molecular changes in serum of major depressive disorder patientsViktoria Stelzhammer, Paul C Guest, Matthias Rothermundt, et al.
Proteomics. Clinical Applications|March 31, 2015
Effects of olanzapine on serum protein phosphorylation patterns in patients with schizophreniaJulian A Jaros, Hassan Rahmoune, Hendrik Wesseling, et al.
Proteomics|August 24, 2013
Development of a novel assay for proprotein converting enzyme activity on a multiplex bead-based array systemAndreas Albrecht, Hassan Rahmoune, Kristi Leedjärv, et al.
Proteomics|May 4, 2011
Characterizing the proteome of the human dorsolateral prefrontal cortex by shotgun mass spectrometryDaniel Martins-de-Souza, Paul C Guest, Hannah Steeb, et al.
NPJ Schizophrenia|June 24, 2016
The association between antibodies to neurotropic pathogens and schizophrenia: a case-control studyLot D de Witte, Hans C van Mierlo, Manja Litjens, et al.
Translational Psychiatry|November 9, 2019
Integrating proteomic, sociodemographic and clinical data to predict future depression diagnosis in subthreshold symptomatic individualsSung Yeon Sarah Han, Jason D Cooper, Sureyya Ozcan, et al.
Pageof 22